AbbVie Acquires Capstan Therapeutics in $2.1 Billion Deal
On Monday, AbbVie announced a major deal to buy Capstan Therapeutics for up to $2.1 billion in cash. This move boosts AbbVie’s lineup of new treatments, focusing on autoimmune diseases, as its top drug, Humira, loses steam. Capstan brings exciting CAR-T therapies to the table, targeting conditions that affect millions.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
